A detailed history of Montag A & Associates Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Montag A & Associates Inc holds 2,000 shares of SAVA stock, worth $50,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,000
Previous 1,500 33.33%
Holding current value
$50,360
Previous $18,000 222.22%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$9.57 - $35.08 $4,785 - $17,540
500 Added 33.33%
2,000 $58,000
Q3 2023

Nov 09, 2023

BUY
$16.64 - $25.32 $8,320 - $12,660
500 Added 50.0%
1,500 $24,000
Q2 2022

Aug 10, 2022

BUY
$17.22 - $38.47 $8,610 - $19,235
500 Added 100.0%
1,000 $28,000
Q4 2021

Feb 09, 2022

SELL
$36.77 - $90.91 $3,493 - $8,636
-95 Reduced 15.97%
500 $21,000
Q2 2021

Aug 03, 2021

BUY
$32.15 - $89.72 $19,129 - $53,383
595 New
595 $51,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.01B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Montag A & Associates Inc Portfolio

Follow Montag A & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Montag A & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Montag A & Associates Inc with notifications on news.